Coffee, Pot Linked to Lower Mortality From Hepatitis C

Increased consumption of coffee and marijuana may sharply reduce the risk for early death from hepatitis C infection, researchers have found. The study of more than 1,200 patients with HCV and HIV found that those who drank the most coffee and used marijuana regularly or daily had more than a 60% lower risk for death from the infection over a five-year period. How cannabis in particular might reduce mortality is unclear, but the researchers, led by Mar

The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...

Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.

Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B virus (HBV)-infection, thus indicating an autoimmune response as possible cause of HCV-infection associated encephalopathy. Data, however, are sparse. This study aims to prove that HCV patients feature sim

Drop in Aussies seeking hepatitis C cure

"Australia is one of the few countries where we can actually eliminate hepatitis C as a public health threat." Three months after starting medication to treat hepatitis C Frank Carlus was cured of the disease that claimed his mother's life. He describes the cure as a godsend, but for his mother the stigma associated with a disease often linked to risky lifestyles was a barrier to her seeking treatment. Hepatitis C can cause liver cancer, cirrhosis a...

FDA OKs First-Line Tx for Unresectable Liver Cancer: First new upfront treatment option in over a decade

WASHINGTON -- The FDA on Thursday approved the kinase inhibitor lenvatinib (Lenvima) for the first-line treatment of hepatocellular carcinoma (HCC) patients with unresectable disease. Approval was based on the REFLECT study, a multicenter non-inferiority trial, which randomized 954 HCC patients 1:1 to either 8 mg or 12 mg oral lenvatinib (depending on the patient's weight) versus 400 mg sorafenib twice daily until disease progression or unacceptable toxic

Patients with chronic HBV die at younger age

Patients with chronic hepatitis B virus infection died an average of 14 years younger and had higher incidences of death from all causes compared with the general U.S. population, according to study results recently published in Clinical Infectious Diseases. “In the United States, about 1,800 death certificates annually list hepatitis B virus (HBV) as an underlying or contributing cause of death,” researchers wrote. “However, accurately quantifying mortal

New online calculator predicts clinical improvement in liver failure after Hep C treatment

Investigators formulated a five-factor metric known as the BE3A score that offers specialists a shared decision-making tool to predict potential improvements after treatment in patients with hepatitis C virus (HCV)-associated liver failure, as detailed in a new study published in Gastroenterology. The five factors in the BE3A score include body mass index (BMI), encephalopathy, ascites, and serum levels of both alanine aminotransferase (ALT) and albumin.

Serum M2BPGi Reliably Assesses Liver Fibrosis in Chronic Hepatitis B

For patients with chronic hepatitis B virus infection (CHB), serum mac-2-binding protein glycosylation isomer (M2BPGi) is a reliable marker for assessing liver fibrosis, according to results published in Clinical and Translational Gastroenterology. M2BPGi presents a noninvasive alternative to the standard invasive liver biopsy for assessing liver fibrosis in CHB. Furthermore, M2BPGi appears to correlate well with histologic stages of liver fibrosis. Af